HC Wainwright Has Positive Forecast for KROS Q2 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Research analysts at HC Wainwright boosted their Q2 2025 earnings per share estimates for shares of Keros Therapeutics in a research note issued to investors on Thursday, May 8th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($1.28) per share for the quarter, up from their previous estimate of ($1.39). HC Wainwright has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for Keros Therapeutics' current full-year earnings is ($4.74) per share. HC Wainwright also issued estimates for Keros Therapeutics' Q3 2025 earnings at ($1.29) EPS, Q4 2025 earnings at ($1.30) EPS, FY2025 earnings at ($0.29) EPS, FY2026 earnings at ($6.07) EPS, FY2027 earnings at ($6.70) EPS, FY2028 earnings at ($4.62) EPS and FY2029 earnings at ($3.04) EPS.

A number of other equities research analysts also recently weighed in on KROS. Cantor Fitzgerald downgraded Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. Scotiabank reduced their price objective on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research report on Monday. Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Truist Financial cut their price objective on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Finally, Wells Fargo & Company cut their price objective on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, February 27th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Keros Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $37.00.

Keros Therapeutics Stock Performance

Keros Therapeutics stock traded up $0.12 on Monday, reaching $13.59. The company's stock had a trading volume of 624,935 shares, compared to its average volume of 825,575. The company has a market cap of $551.96 million, a price-to-earnings ratio of -2.61 and a beta of 1.32. The business's fifty day moving average price is $12.27 and its 200 day moving average price is $23.83. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $211.25 million for the quarter, compared to analyst estimates of $84.62 million. During the same quarter last year, the firm posted ($1.21) EPS.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the business's stock in a transaction on Wednesday, April 9th. The shares were acquired at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the purchase, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 22.90% of the company's stock.

Hedge Funds Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of KROS. Barclays PLC grew its position in shares of Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company's stock valued at $3,484,000 after purchasing an additional 35,022 shares in the last quarter. SG Americas Securities LLC bought a new stake in Keros Therapeutics in the fourth quarter worth about $388,000. Exchange Traded Concepts LLC bought a new stake in shares of Keros Therapeutics during the fourth quarter valued at approximately $99,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Keros Therapeutics by 19.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock valued at $136,000 after acquiring an additional 1,372 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its stake in Keros Therapeutics by 11.3% in the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock worth $171,000 after buying an additional 1,100 shares in the last quarter. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.